Viking Therapeutics, Inc.VKTXEarnings & Financial Report
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for endocrine, metabolic and inflammatory disorders with high unmet medical need. Its pipeline includes lead product candidates targeting non-alcoholic steatohepatitis (NASH), dyslipidemia, and hypogonadism, serving global patient populations across major regional markets.
VKTX Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-164.7M
Net Profit
$-157.7M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-1.39
Viking Therapeutics, Inc. Q4 FY2025 Financial Summary
Viking Therapeutics, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of $-157.7M (down 345.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-157.7M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Viking Therapeutics, Inc. Annual Revenue by Year
Viking Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
Viking Therapeutics, Inc. Quarterly Revenue & Net Profit History
Viking Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-157.7M | N/A |
| Q3 FY2025 | $0 | — | $-90.8M | N/A |
| Q2 FY2025 | $0 | — | $-65.6M | N/A |
| Q1 FY2025 | $0 | — | $-45.6M | N/A |
| Q4 FY2024 | $0 | — | $-35.4M | N/A |
| Q3 FY2024 | $0 | — | $-24.9M | N/A |
| Q2 FY2024 | $0 | — | $-22.3M | N/A |
| Q1 FY2024 | $0 | — | $-27.4M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $967.5M | $946.8M | $937.9M | $908.3M | $867.0M | $827.9M | $739.4M | $715.7M |
| Liabilities | $33.6M | $25.9M | $26.4M | $28.0M | $20.1M | $32.4M | $26.4M | $76.7M |
| Equity | $933.9M | $921.0M | $911.4M | $880.3M | $846.9M | $795.5M | $713.0M | $639.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.1M | $-28.5M | $-22.0M | $-31.2M | $-52.3M | $-47.1M | $-94.0M | $-85.3M |